|
1. |
Treatment Research at the MillenniumFrom Efficacy to Effectiveness |
|
Journal of Clinical Psychopharmacology,
Volume 18,
Issue 1,
1998,
Page 1-1
Barry D. Lebowitz,
Matthew V. Rudorfer,
Preview
|
|
ISSN:0271-0749
出版商:OVID
年代:1998
数据来源: OVID
|
2. |
Pharmacokinetic Interactions of Clozapine With Selective Serotonin Reuptake InhibitorsDifferential Effects of Fluvoxamine and Paroxetine in a Prospective Study |
|
Journal of Clinical Psychopharmacology,
Volume 18,
Issue 1,
1998,
Page 2-9
Hermann Wetzel,
Ion Anghelescu,
Armin Szegedi,
Jasmin Wiesner,
Harald MD Weigmann,
Sebastian Hartter,
Christoph Hiemke,
Preview
|
|
摘要:
Pharmacokinetic interactions of clozapine and its metabolites N-desmethylclozapine and clozapine N-oxide with the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine and paroxetine were investigated in a prospective study in schizophrenic patients under steady-state conditions. Thirty patients were treated with clozapine at a target dose of 2.5 to 3.0 mg/kg of body weight. After gradual dose escalation, serum concentrations of clozapine and two metabolites were determined twice at 7-day intervals after steady-state conditions had been reached. Then, fluvoxamine (50 mg/day) or paroxetine (20 mg/day) was added in 16 and 14 patients, respectively. Serum concentrations of clozapine and its metabolites were measured after 1, 7, and 14 days of coadministration with the SSRI. Mean trough concentrations of steady-state serum concentrations of clozapine, N-desmethylclozapine, and clozapine N-oxide were markedly elevated under fluvoxamine by about threefold of baseline concentrations whereas paroxetine induced only minor, nonsignificant changes. Estimation of the mean elimination half-life of clozapine 2 weeks after start of fluvoxamine comedication revealed an increase from 17 hours to about 50 hours whereas there was no change under paroxetine coadministration. The N-desmethylclozapine/clozapine ratio did not change significantly with either SSRI. Under monotherapy, clozapine mean serum concentrations in smokers were significantly lower by 32% compared with nonsmokers. Similarly, N-demethylation ratios were about 20 to 50% higher in smokers. Thus, in all patients, fluvoxamine induced relevant increases in serum concentrations of clozapine and its metabolites, probably by the inhibition of enzymes catalyzing the degradation of clozapine and N-desmethylclozapine, whereas paroxetine, at a usual clinically effective dosage of 20 mg/day, did not cause significant pharmacokinetic interactions. (J Clin Psychopharmacol 1998;18:2-9)
ISSN:0271-0749
出版商:OVID
年代:1998
数据来源: OVID
|
3. |
An Open Trial of Paroxetine in Patients With Noncombat-Related, Chronic Posttraumatic Stress Disorder |
|
Journal of Clinical Psychopharmacology,
Volume 18,
Issue 1,
1998,
Page 10-18
Randall D. Marshall,
Franklin R. Schneier,
Brian A. Fallon,
Charles B. G. Knight,
Linda A. Abbate,
Deborah Goetz,
Raphael Campeas,
Michael R. Liebowitz,
Preview
|
|
摘要:
The symptom overlap between posttraumatic stress disorder (PTSD) and other pharmacotherapy-responsive disorders suggests that pharmacotherapy might be effective. Nevertheless, of the eight published placebo-controlled trials investigating the pharmacotherapy of PTSD, only four found statistically significant efficacy for the treatment being studied. This literature possesses a number of methodologic limitations, including the fact that most studies have been conducted with war veterans, who may constitute a more treatment-refractory population. Several open trials and one controlled trial with selective serotonin reuptake inhibitors have reported improvement in some or all core PTSD symptoms (reexperiencing, avoidance, numbing, and hyper-arousal). The authors hypothesized that paroxetine might be effective in PTSD, based on findings of its particular efficacy for anxiety and agitation in studies of depressed patients. The study presented here summarizes a 12-week, open-label trial of paroxetine among patients with noncombat-related, chronic PTSD. Outcome was assessed by an independent evaluator, the treating physician, and the patient, with the use of established rating scales for depression, anxiety, general symptoms, and PTSD core symptoms. A repeated-measures analysis of variance revealed highly significant improvement in all three symptom clusters, as well as in associated anxiety, depressive, and dissociative symptoms, with 11 of 17 (65%) patients rated as much or very much improved. The mean reduction in PTSD symptom scores was 48%. Exploratory analyses revealed that cumulative childhood trauma was negatively correlated with pharmacotherapy response (r = -0.52, p = 0.03). There was also significant variation in the time course of response across symptom clusters, which is suggestive of multiple mechanisms of response. Because paroxetine seems a highly promising treatment for all three symptom clusters of PTSD, a placebo-controlled clinical trial is warranted. (J Clin Psychopharmacol 1998;18:10-18)
ISSN:0271-0749
出版商:OVID
年代:1998
数据来源: OVID
|
4. |
The Use of Venlafaxine in the Treatment of Major Depression and Major Depression Associated With AnxietyA Dose-Response Study |
|
Journal of Clinical Psychopharmacology,
Volume 18,
Issue 1,
1998,
Page 19-25
Arifulla Khan,
G. Virginia Upton,
Richard L. Rudolph,
Richard Entsuah,
Steven M. Leventer,
Preview
|
|
摘要:
This 12-week, double-blind, placebo-controlled study evaluated the efficacy and safety of venlafaxine as first-line therapy for the treatment of major depression and major depression associated with anxiety in 384 adult outpatients. Fixed total daily dosages of 75, 150, and 200 mg of venlafaxine were administered in a twice-a-day regimen. Primary efficacy parameters were the Hamilton Rating Scale for Depression (HAM-D) total score, the HAM-D Depressed Mood Item, the Montgomery-Asberg Depression Rating Scale total score, and the Clinical Global Impressions Scale. Overall, a higher percentage of patients responded to venlafaxine than to placebo. Efficacy data indicated a dose-related response, most evident in the onset of clinical improvement; statistically significant improvements in some primary parameters were seen as early as 1 to 2 weeks after initiation of treatment, especially in the 150- and 200-mg/day groups. These dose-related clinical improvements continued through week 12. Venlafaxine-treated patients who had depression associated with anxiety showed significant dose-related improvements compared with placebo-treated patients; improvement was noted by scores on the HAM-D Anxiety-Psychic Item and Anxiety-Somatization Factor. Few clinically significant changes were observed in laboratory values, vital signs, or electrocardiogram tracings. Venlafaxine was generally well tolerated at all dosages. The most common study events included nausea, dizziness, somnolence, insomnia, dry mouth, and asthenia, which are consistent with findings of previous studies. The current study demonstrated that 75 to 200 mg/day of venlafaxine twice daily produced a dose-related improvement in the primary efficacy parameters and in the onset of significant antidepressant effects, which was noted at weeks 1 to 2 with the highest dosage tested (200 mg/day). The study also demonstrated that these dosages of venlafaxine were safe and effective as first-line therapy for major depression and depression associated with anxiety. (J Clin Psychopharmacol 1998;18:19-25).
ISSN:0271-0749
出版商:OVID
年代:1998
数据来源: OVID
|
5. |
Fluoxetine Normalizes Increased Cardiac Vagal Tone in Bulimia Nervosa |
|
Journal of Clinical Psychopharmacology,
Volume 18,
Issue 1,
1998,
Page 26-32
Aila Rissanen,
Hannu Naukkarinen,
Matti Virkkunen,
Robert R. Rawlings,
Markku Linnoila,
Preview
|
|
摘要:
Patients with bulimia nervosa have been reported to respond to treatment with the serotonin uptake inhibitor fluoxetine.In a preliminary study, which had a small sample size, women with bulimia nervosa were reported to have elevated cardiac vagal tone. We investigated cardiac vagal tone in women with bulimia nervosa before and after treatment with fluoxetine.At baseline, resting cardiac vagal tone, deduced from the respiratory component of heart rate variability, was quantified in 41 healthy volunteer women and in 25 women with bulimia nervosa.The bulimic women received in a parallel-group design, double blind, either placebo or fluoxetine 60 mg/24 hr for 8 weeks. All patients participated in behavioral therapy. Resting cardiac vagal tone was measured again at the end of the treatment.Women with bulimia nervosa had higher cardiac vagal tone than age-matched healthy volunteer women. Placebo had no effect on cardiac vagal tone. Fluoxetine reduced cardiac vagal tone among the women with bulimia nervosa to a level similar to the healthy volunteer women.Women with bulimia nervosa have elevated resting cardiac vagal tone.Fluoxetine normalized the elevated resting cardiac vagal tone among the women with bulimia nervosa. At both the central and peripheral levels, vagal neurons are endowed with serotonin-3 receptors. In vitro, fluoxetine desensitizes or blocks serotonin-3 receptors. A controlled trial of serotonin-3 receptor blockers is warranted in bulimia nervosa. (J Clin Psychopharmacol 1998;18:26-32)
ISSN:0271-0749
出版商:OVID
年代:1998
数据来源: OVID
|
6. |
Increased Lithium Serum and Red Blood Cell Concentrations During Ketorolac Coadministration |
|
Journal of Clinical Psychopharmacology,
Volume 18,
Issue 1,
1998,
Page 33-37
Julie A. Cold,
Troy L. Zumbrunnen,
M. Andy Simpson,
Bruce G. Augustin,
Eric Awad,
Michael W. Jann,
Preview
|
|
摘要:
Case reports of a lithium-ketorolac drug interaction have been published, but no formal investigation of this interaction has been conducted. The objective of the study presented here was to determine significant changes in lithium serum and red blood cell (RBC) concentrations after lithium and ketorolac (oral formulation) coadministration at steady-state conditions. Five healthy men participated in the study and received lithium 900 mg/day (300 mg in the morning and 600 mg at bedtime) for 13 days. Ketorolac 40 mg/day (10 mg four times a day) was added on days 8 through 12. Ten blood samples were obtained on days 7 and 13 to determine area under the concentration-time curve (AUC) lithium serum and RBC concentrations. Serum and RBC lithium concentrations were assayed by atomic absorption spectrophotometry with an intra-assay coefficient of variation (CV) of 1.2% on day 1 (range 0-1.0 micro gram/mL) and 4.9% (range 0-1.0 micro gram/mL) on day 2 and an interassay CV of 2.9% (range 0-1.0 micro gram/mL) on days 1 and 2 of serum analysis and a CV of 5.3% (range 0-0.3 micro gram/mL) of RBC concentrations. Total serum AUC lithium and RBC AUC values significantly increased by 24% (p < 0.02) and by 27% (p < 0.05) with the ketorolac coadministration, respectively. An increased incidence and severity of lithium-associated side effects were reported during concomitant administration. A clinically significant drug interaction can occur when ketorolac is added to lithium therapy. (J Clin Psychopharmacol 1998;18:33-37)
ISSN:0271-0749
出版商:OVID
年代:1998
数据来源: OVID
|
7. |
Lithium Plus Valproate as Maintenance Polypharmacy for Patients With Bipolar I DisorderA Review |
|
Journal of Clinical Psychopharmacology,
Volume 18,
Issue 1,
1998,
Page 38-49
David A. Solomon,
Gabor I. Keitner,
Christine E. Ryan,
Ivan W. Miller,
Preview
|
|
摘要:
Standard pharmacotherapy for the maintenance treatment of patients with bipolar I disorder consists of lithium, valproate, or carbamazepine.However, many patients fail to respond to monotherapy with any of these agents, and as a result, psychiatrists often resort to polypharmacy. Findings from some open-label trials and retrospective chart reviews suggest this approach may be useful, but in the few controlled trials that have been conducted, the results have been negative. One drug combination that warrants further study as maintenance therapy is lithium plus valproate. Each is approved by the U.S. Food and Drug Administration for treatment of acute mania, and lithium has demonstrated efficacy for maintenance treatment as well. Some preliminary evidence suggests that the combination can be effective for patients who do not respond to monotherapy, and it seems to be no more dangerous than monotherapy. Concomitant administration of lithium plus valproate does not significantly alter lithium pharmacokinetics, and statistically significant changes that arise in valproate pharmacokinetics are not clinically significant. Although it is not known whether the drugs interact to augment response, many of their effects in the central nervous system do differ, and there is no indication of pharmacodynamic interactions that oppose each other. Finally, some evidence suggests that lithium and valproate may differ with regard to clinical variables that predict response to treatment. (J Clin Psychopharmacol 1998;18:38-49)
ISSN:0271-0749
出版商:OVID
年代:1998
数据来源: OVID
|
8. |
Drug-Induced StutteringA Review of the Literature |
|
Journal of Clinical Psychopharmacology,
Volume 18,
Issue 1,
1998,
Page 50-54
John Paul Brady,
Preview
|
|
摘要:
The author critically reviews the world literature on drug-induced stuttering. The literature on stuttering as a side effect of pharmacologic agents was identified by means of a computer-assisted search. A diversity of drugs has been reported to induce stuttering in susceptible persons, including some agents that improve the speech of some known stutterers. In all instances, normal speech returned shortly after the offending drug was discontinued. Multiple, interacting neurotransmitter systems seem to be involved. Drug-induced imbalances in these systems may account for the speech disturbances. (J Clin Psychopharmacol 1998;18:50-54)
ISSN:0271-0749
出版商:OVID
年代:1998
数据来源: OVID
|
9. |
The Extent and Determinants of Changes in CYP2D6 and CYP1A2 Activities With Therapeutic Doses of Sertraline |
|
Journal of Clinical Psychopharmacology,
Volume 18,
Issue 1,
1998,
Page 55-61
Vural Ozdemir,
Claudio A. Naranjo,
Nathan Herrmann,
Richard W. Shulman,
Edward M. Sellers,
Ken Reed,
Werner Kalow,
Preview
|
|
摘要:
0.05). In conclusion, sertraline treatment at a mean daily dosage of 94.0 mg did not significantly change CYP1A2 activity and resulted in a modest inhibition of CYP2D6 activity. (J Clin Psychopharmacol 1998;18:55-61).
ISSN:0271-0749
出版商:OVID
年代:1998
数据来源: OVID
|
10. |
Sertraline in Adults With Pervasive Developmental DisordersA Prospective Open-Label Investigation |
|
Journal of Clinical Psychopharmacology,
Volume 18,
Issue 1,
1998,
Page 62-66
Christopher J. McDougle,
Edward S. Brodkin,
Susan T. Naylor,
Derek C. Carlson,
Donald J. Cohen,
Lawrence H. Price,
Preview
|
|
摘要:
The short-term efficacy and tolerability of sertraline for adults with pervasive developmental disorders (PDDs) were assessed in this investigation. Forty-two adults with PDDs (autistic disorder, N = 22; Asperger's disorder, N = 6; and PDD not otherwise specified [NOS], N = 14) participated in a 12-week, open-label, systematic trial of sertraline. Behavioral ratings of repetitive symptoms, aggression, and social relatedness were obtained at baseline and after 4, 8, and 12 weeks of sertraline administration. Twenty-four (57%) of 42 patients showed significant improvement, primarily in repetitive and aggressive symptoms. Statistically significant changes in measures of social relatedness did not occur. Patients with autistic disorder and PDD NOS did significantly better than those with Asperger's disorder. Based on global improvement item criteria from the Clinical Global Impression Scale, 15 of 22 (68%) patients with autistic disorder, none of six (0%) patients with Asperger's disorder, and 9 of 14 (64%) patients with PDD NOS were categorized as treatment responders. Sertraline was well tolerated; no adverse cardiovascular effects, extrapyramidal symptoms, or seizures were identified. These findings suggested that sertraline may be an effective treatment for interfering repetitive and aggressive symptoms in adults with PDDs. Definitive statements about the efficacy and tolerability of sertraline for treating adults with PDDs must await results from double-blind, placebo-controlled trials. These preliminary results should not be generalized to include children and adolescents with PDDs. (J Clin Psychopharmacol 1998;18:62-66)
ISSN:0271-0749
出版商:OVID
年代:1998
数据来源: OVID
|
|